The Isothermal Nucleic Acid Amplification Technology Market Size is valued at USD 4.53 Bn in 2023 and is predicted to reach USD 8.91 Bn by the year 2031 at a 8.94% CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- Increasing disposable income and better healthcare facilities in emerging countries should boost the isothermal nucleic acid amplification technology industry.
- Isothermal nucleic acid amplification technology has surged due to high demand in research and development activities and an increased focus on biomarker discovery.
- North America dominated the market and accounted for a revenue share of global revenue in 2023.
- The regulatory structure that controls the creation and utilization of INAAT-based diagnostic and therapeutic techniques is a big roadblock limiting the market's development.
The Isothermal Nucleic Acid Amplification Technology (INAAT) is seeing a significant increase in demand as a molecular testing technique, owing mostly to the increasing prevalence of infectious diseases. Infectious diseases such as hepatitis, influenza, and others are among the main causes of death, particularly in underdeveloped nations. As a result, the demand for quick, easy-to-use, disease-specific testing alternatives is predicted to drive up the adoption of INAAT solutions.
Rapid advancements in existing amplification technologies, as well as the development of technologies such as Single Primer Isothermal Amplification, Loop-Mediated Isothermal Amplification, Recombinase Polymerase Amplification, and others, are paving the way for new INAAT product applications. For example, in June 2022, a research study published in the Analyst Journal demonstrated the creation of smartphone-integrated equipment that can rapidly test for the Zika virus in a single blood drop utilizing LAMP technology. Such advancements are likely to increase the technique's commercial penetration shortly.
Competitive Landscape:
Some major key players in the Isothermal Nucleic Acid Amplification Technology Market:
- Grifols, S.A. (Spain),
- Hologic, Inc. (US),
- Abbott Laboratories (US),
- Becton, Dickinson and Company (US),
- Meridian Bioscience (US),
- Eiken Chemical Co., Ltd. (Japan),
- bioMérieux SA (France),
- Tecan Trading AG (Switzerland),
- New England Biolabs (US),
- QIAGEN N.V. (Germany),
- DiaSorin Sp.A. (Italy),
- General Electric (US),
- OptiGene Limited (UK),
- Quidel Corporation (US),
- Thermo Fisher Scientific (US).
- Genomtec (Poland),
- Mast Group Ltd. (UK),
- Ustar Biotechnologies (China),
- Jena Bioscience GmbH (Germany),
- Atila BioSystems (US),
- TwistDx Limited (UK),
- LGC Limited (UK),
- Life Sciences Advanced Technologies (US),
- GenoSensor Corporation (US),
- PCR Biosystems (UK)
Market Segmentation:
The INAAT market has been divided based on product, technology, application, and end-user. The market is segmented as assays and systems based on product. The technology segment includes TMA, LAMP, SDA, NASBA, SPIA, NEAR, and HDA. The application segment includes diagnosis, blood screening, and other applications. As per the end-users, the market is bifurcated into hospitals, reference laboratories, academic & research laboratories, and other end-users.
Based On Technology, The LAMP Segment Is Accounted As A Major Contributor In The Isothermal Nucleic Acid Amplification Technology Market
The highest market share was held by loop-mediated isothermal amplification (LAMP). The method allows for several detection modes, such as real-time fluorescence using intercalators, lateral flow, and agarose gel detection. As a result, the approach can detect a wide spectrum of RNA and DNA targets in human samples, including the Zika virus and SARS-CoV-2 virus. Furthermore, the technique's resistance to inhibitors allows it to be used with crude samples and little processed nucleic acids, which increasesdemand.
The Hospital Segment Witnessed The Development At A Rapid Rate
The hospital segment dominated the market. This is due to the introduction of miniaturized point-of-care INAAT equipment that allows for single-level access for hospital-based analysis. Similarly, the increased throughput and automation provided by such technologies for the processing of a high number of samples are likely to drive market expansion.
In The Region, The North America Isothermal Nucleic Acid Amplification Technology Market Holds A Significant Revenue Share
North America dominated the market due to the region's existing research infrastructure and rising demand for nucleic acid amplification-based diagnostics for infectious disease prevention. Furthermore, high per capita healthcare spending and a growing emphasis on point-of-care diagnostic methods are expected to boost market expansion.
Recent Developments
- In May 2022, Meridian Bioscience launched Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for direct detection of DNA & RNA in point-of-care diagnostic assays. Lyo-Ready™ Direct DNA LAMP Saliva Mix and Lyo-Ready™ Direct RNA/DNA LAMP Saliva Mix were the first isothermal mixes specifically designed for saliva and sputum samples, and they were compatible with lyophilization.
- In March 2022, Thermo Fisher Scientific introduced two novel solutions based on reverse transcription loop-mediated isothermal amplification (RT-LAMP). The isothermal RT-LAMP method, which relies on nucleic acid amplification, offers a fast and cost-effective approach for detecting viral pathogens.
Isothermal Nucleic Acid Amplification Technology Market Report Scope:
Report Attribute |
Specifications |
Market Size Value In 2023 |
USD 4.53 Bn |
Revenue Forecast In 2031 |
USD 8.91 Bn |
Growth Rate CAGR |
CAGR of 8.94% from 2024 to 2031 |
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
Historic Year |
2019 to 2023 |
Forecast Year |
2024-2031 |
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
Segments Covered |
By Product, Technology, Application, End-User |
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
Competitive Landscape |
Grifols, S.A. (Spain), Hologic, Inc. (US), Abbott Laboratories (US), Becton, Dickinson and Company (US), Meridian Bioscience (US), Eiken Chemical Co., Ltd. (Japan), bioMérieux SA (France), Tecan Trading AG (Switzerland), New England Biolabs (US), QIAGEN N.V. (Germany), DiaSorin Sp.A. (Italy), General Electric (US), OptiGene Limited (UK), Quidel Corporation (US), Thermo Fisher Scientific (US). Genomtec (Poland), Mast Group Ltd. (UK), Ustar Biotechnologies (China), Jena Bioscience GmbH (Germany), Atila BioSystems (US), TwistDx Limited (UK), LGC Limited (UK), Life Sciences Advanced Technologies (US), GenoSensor Corporation (US), and PCR Biosystems (UK). |
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |